BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12569483)

  • 1. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex.
    Ernst JT; Becerril J; Park HS; Yin H; Hamilton AD
    Angew Chem Int Ed Engl; 2003 Feb; 42(5):535-9. PubMed ID: 12569483
    [No Abstract]   [Full Text] [Related]  

  • 2. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
    Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
    J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction.
    Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD
    J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold.
    Antuch W; Menon S; Chen QZ; Lu Y; Sakamuri S; Beck B; Schauer-Vukasinović V; Agarwal S; Hess S; Dömling A
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1740-3. PubMed ID: 16427279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors.
    Yap JL; Cao X; Vanommeslaeghe K; Jung KY; Peddaboina C; Wilder PT; Nan A; MacKerell AD; Smythe WR; Fletcher S
    Org Biomol Chem; 2012 Apr; 10(15):2928-33. PubMed ID: 22395339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations.
    Lama D; Sankararamakrishnan R
    Proteins; 2008 Nov; 73(2):492-514. PubMed ID: 18452209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
    Sattler M; Liang H; Nettesheim D; Meadows RP; Harlan JE; Eberstadt M; Yoon HS; Shuker SB; Chang BS; Minn AJ; Thompson CB; Fesik SW
    Science; 1997 Feb; 275(5302):983-6. PubMed ID: 9020082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry.
    Kutzki O; Park HS; Ernst JT; Orner BP; Yin H; Hamilton AD
    J Am Chem Soc; 2002 Oct; 124(40):11838-9. PubMed ID: 12358513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins.
    Moreau C; Cartron PF; Hunt A; Meflah K; Green DR; Evan G; Vallette FM; Juin P
    J Biol Chem; 2003 May; 278(21):19426-35. PubMed ID: 12642586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL.
    Degterev A; Lugovskoy A; Cardone M; Mulley B; Wagner G; Mitchison T; Yuan J
    Nat Cell Biol; 2001 Feb; 3(2):173-82. PubMed ID: 11175750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein.
    Yin H; Hamilton AD
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1375-9. PubMed ID: 15006365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-face, two-turn α-helix mimetics based on a cross-acridine scaffold: analogues of the Bim BH3 domain.
    Li X; Wang Z; Feng Y; Song T; Su P; Chen C; Chai G; Yang Y; Zhang Z
    Chembiochem; 2014 Jun; 15(9):1280-5. PubMed ID: 24838655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members.
    Diaz JL; Oltersdorf T; Horne W; McConnell M; Wilson G; Weeks S; Garcia T; Fritz LC
    J Biol Chem; 1997 Apr; 272(17):11350-5. PubMed ID: 9111042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular dynamics study of peptide segments of the BH3 domain of the proapoptotic proteins Bak, Bax, Bid and Hrk bound to the Bcl-xL and Bcl-2 proteins.
    Pinto M; Perez JJ; Rubio-Martinez J
    J Comput Aided Mol Des; 2004 Jan; 18(1):13-22. PubMed ID: 15143800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions.
    Finnegan NM; Curtin JF; Prevost G; Morgan B; Cotter TG
    Br J Cancer; 2001 Jul; 85(1):115-21. PubMed ID: 11437412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear magnetic resonance study of protein-protein interactions involving apoptosis regulator Diva (Boo) and the BH3 domain of proapoptotic Bcl-2 members.
    Santiveri CM; Sborgi L; de Alba E
    J Mol Recognit; 2012 Dec; 25(12):665-73. PubMed ID: 23192964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane-insertion fragments of Bcl-xL, Bax, and Bid.
    García-Sáez AJ; Mingarro I; Pérez-Payá E; Salgado J
    Biochemistry; 2004 Aug; 43(34):10930-43. PubMed ID: 15323553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of two strategies for affinity maturation of a BH3 peptide toward pro-survival Bcl-2 proteins.
    Zhang S; Long A; Link AJ
    ACS Synth Biol; 2012 Mar; 1(3):89-98. PubMed ID: 23651073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain.
    Boersma MD; Haase HS; Peterson-Kaufman KJ; Lee EF; Clarke OB; Colman PM; Smith BJ; Horne WS; Fairlie WD; Gellman SH
    J Am Chem Soc; 2012 Jan; 134(1):315-23. PubMed ID: 22040025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the anti-apoptotic mechanism of Bcl-B.
    Zhai D; Ke N; Zhang H; Ladror U; Joseph M; Eichinger A; Godzik A; Ng SC; Reed JC
    Biochem J; 2003 Nov; 376(Pt 1):229-36. PubMed ID: 12921534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.